Neogen Corp.

How big is Neogen Corp.?

As of Jun 18, Neogen Corp. has a market capitalization of 1,145.96 million, classifying it as a Small Cap company, with net sales of 905.99 million and a net profit of -485.27 million over the latest four quarters.

Market Cap: As of Jun 18, Neogen Corp. has a market capitalization of 1,145.96 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Neogen Corp. reported net sales of 905.99 million and a net profit of -485.27 million.<BR><BR>Balance Sheet Snapshot: As of May 24, the company reported shareholder's funds of 3,144.14 million and total assets of 4,584.16 million.

What does Neogen Corp. do?

Neogen Corp. develops and markets products for food and animal safety within the Pharmaceuticals & Biotechnology industry. As of February 2025, it has net sales of $221 million, a net profit of -$11 million, and a market cap of approximately $1.15 billion.

Overview:<BR>Neogen Corp. develops, manufactures, and markets products and services dedicated to food and animal safety, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 221 Million (Quarterly Results - Feb 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Feb 2025) <BR>Market-cap: USD 1,145.96 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 281.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.29 <BR>Return on Equity: 0.15% <BR>Price to Book: 0.43<BR><BR>Contact Details:<BR>Address: 620 Lesher Pl, LANSING MI: 48912-1509 <BR>Tel: 1 517 3729200 <BR>Fax: 1 517 3722006 <BR>Website: http://www.neogen.com/

Should I buy, sell or hold Neogen Corp.?

Who are in the management team of Neogen Corp.?

As of March 2022, Neogen Corp.'s management team includes CEO John Adent and Lead Independent Chairman James Borel, along with several independent directors: Dr. William Boehm, Dr. Ronald Green, Mr. G. Bruce Papesh, Mr. James Tobin, and Ms. Darci Vetter.

As of March 2022, the management team of Neogen Corp. includes the following individuals:<BR><BR>- Mr. James Borel, who serves as the Lead Independent Chairman of the Board.<BR>- Mr. John Adent, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. William Boehm, who is an Independent Director.<BR>- Dr. Ronald Green, who is also an Independent Director.<BR>- Mr. G. Bruce Papesh, serving as an Independent Director.<BR>- Mr. James Tobin, who is an Independent Director.<BR>- Ms. Darci Vetter, who is an Independent Director.<BR><BR>In summary, the management team comprises a mix of leadership roles, including the CEO and several independent directors.

Is Neogen Corp. overvalued or undervalued?

As of July 30, 2024, Neogen Corp. is considered overvalued and risky, with a high P/E ratio of 281, a low Price to Book Value of 0.42, and poor performance reflected in a YTD return of -53.29% and a 10Y return of -84.97%, significantly underperforming compared to its peers and the S&P 500.

As of 30 July 2024, the valuation grade for Neogen Corp. has moved from expensive to risky, indicating a significant shift in its perceived value. Based on the current metrics, Neogen Corp. appears to be overvalued. The P/E ratio stands at an exceptionally high 281, while the Price to Book Value is only 0.42, suggesting that the market price is not justified by the company's book value. Additionally, the EV to EBITDA ratio is 10.94, which further highlights the disparity between the company's valuation and its earnings potential.<BR><BR>In comparison to its peers, Neogen Corp. has a P/E ratio that is significantly higher than Masimo Corp. at 179.74 and Globus Medical, Inc. at 18.37, both of which are in a better valuation position. Furthermore, the company's return performance has been notably poor, with a YTD return of -53.29% compared to the S&P 500's 12.22%, and a staggering 10Y return of -84.97% against the S&P 500's 231.64%. This stark contrast reinforces the notion that Neogen Corp. is not only overvalued but also struggling significantly in the market.

Is Neogen Corp. technically bullish or bearish?

As of August 12, 2025, Neogen Corp. shows a mildly bearish technical trend with mixed signals from various indicators, significantly underperforming the S&P 500 year-to-date and over the past year.

As of 12 August 2025, the technical trend for Neogen Corp. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The Bollinger Bands show a bullish stance on the weekly chart but are bearish on the monthly. Moving averages are mildly bearish on the daily timeframe. The KST is mildly bullish weekly but bearish monthly, while the Dow Theory indicates a mildly bearish weekly and mildly bullish monthly trend. The OBV shows a mildly bearish weekly and mildly bullish monthly trend as well.<BR><BR>In terms of performance, Neogen Corp. has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -53.29% compared to the S&P 500's 12.22%, and a one-year return of -67.11% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, reflecting a weak outlook despite some bullish indicators on shorter timeframes.